Proactiveinvestors recommends
Additional Information
Market: TSXV
Sector: Pharmaceuticals
EPIC: MDG
Medicago
www.medicago.com/en

Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants.

Full Medicago profile here
Pdf

Medicago’s Swine flu vaccine candidate shows 100 pct positive response after single dose in animals

30th Jul 2009, 3:42 pm
Medicago’s Swine flu vaccine candidate shows 100 pct positive response after single dose in animals

Biotech group Medicago Inc (TSX-V: MDG) said latest results from animal trials testing its Swine flu vaccine candidate showed that a single dose of 5 micrograms induced a positive immune response against a new emerging strain of this virus in 100 percent of vaccinated animals.

Medicago's Influenza A H1N1 Virus-Like Particles vaccine was formulated to protect against the influenza A/California/04/09 virus, which was one of the original viral strains selected by the WHO for vaccine manufacturers.

The company previously reported data from an initial study in mice where its novel vaccine achieved a positive immune response in 100 percent of the animals vaccinated against the California/04 virus.

In a continuation of this study, Medicago tested the immune response of its H1N1 vaccine against the California/07 virus, a more current and mutated strain and showed positive immune response after a single dose of 5 micrograms. The challenge of current pandemic influenza vaccines is they have to match the circulating strain in order to be effective.

These additional data expand upon the results we announced in June and support our belief that our influenza vaccines are also capable of providing protection against different circulating viral strains," said Andy Sheldon, President and CEO of Medicago.

"Unlike current vaccine manufacturers that have experienced difficulties producing a pandemic candidate for H1N1, our H1N1 vaccine candidate was well expressed in our plant-based system and has produced good yields."

Vaccine makers currently developing vaccine candidates for the pandemic swine flu using egg-based and cell culture technologies have advised the WHO that the influenza seed strain used to produce their new vaccine is not growing well and therefore giving poor antigen yields. The yield is approximately 25-50 percent of that vaccine makers typically get for seasonal flu vaccine production.

The WHO recently made a new set of seed strains using new viral isolates, such as the California/07, in the hope of increasing the vaccine yield. Medicago's vaccine is produced using its VLP technology that does not require a virus and therefore does not rely on the ability of a viral strain to grow.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.